Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis

References

• Abdollahi, S., A. Salehi‐Abargouei, O. Toupchian, M. Hasan Sheikhha, H. Fallahzadeh, M. Rahmanian, M. Tabatabaie, and H. Mozaffari‐Khosravi. 2019. The effect of resveratrol supplementation on cardio-metabolic risk factors in patients with type 2 diabetes: A randomized, double-blind controlled trial. Phytotherapy Research 33 (12):3153–62. doi: 10.1002/ptr.6487.
   PubMedGoogle Scholar
• Anton, S. D., C. Embry, M. Marsiske, X. Lu, H. Doss, C. Leeuwenburgh, and T. M. Manini. 2014. Safety and metabolic outcomes of resveratrol supplementation in older adults: Results of a twelve-week, placebo-controlled pilot study. Experimental Gerontology 57:181–7. doi: 10.1016/j.exger.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Arzola-Paniagua, M. A., E. R. García-Salgado López, C. G. Calvo-Vargas, and M. Guevara-Cruz. 2016. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. Obesity 24 (7):1454–63. doi: 10.1002/oby.21523.
   PubMed Web of Science ®Google Scholar
• Banaszewska, B., J. Wrotyńska-Barczyńska, R. Z. Spaczynski, L. Pawelczyk, and A. J. Duleba. 2016. Effects of resveratrol on polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 101: 4322–28. doi: 10.1210/jc.2016-1858.
   PubMed Web of Science ®Google Scholar
• Bhatt, J. K., S. Thomas, and M. J. Nanjan. 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research 32 (7):537–41. doi: 10.1016/j.nutres.2012.06.003.
   PubMed Web of Science ®Google Scholar
• Bo, S., V. Ponzo, G. Ciccone, A. Evangelista, F. Saba, I. Goitre, M. Procopio, G. F. Pagano, M. Cassader, and R. Gambino. 2016. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacological Research 111:896–905. doi: 10.1016/j.phrs.2016.08.010.
   PubMed Web of Science ®Google Scholar
• Borenstein, M., L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein. 2009. Introduction to meta-analysis. 1–421. doi: 10.1002/9780470743386.
   Google Scholar
• Brasnyó, P., G. A. Molnár, M. Mohás, L. Markó, B. Laczy, J. Cseh, E. Mikolás, I. A. Szijártó, Á. Mérei, R. Halmai, et al. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition 106 (3):383–9. doi: 10.1017/S0007114511000316.
   PubMed Web of Science ®Google Scholar
• Brown, V. A., K. R. Patel, M. Viskaduraki, J. A. Crowell, M. Perloff, T. D. Booth, G. Vasilinin, A. Sen, A. M. Schinas, G. Piccirilli, et al. 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Research 70 (22):9003–11. doi: 10.1158/0008-5472.CAN-10-2364.
   PubMed Web of Science ®Google Scholar
• Catalgol, B., S. Batirel, Y. Taga, and N. K. Ozer. 2012. Resveratrol: French paradox revisited. Frontiers in Pharmacology 3: 141. doi: 10.3389/fphar.2012.00141.
   PubMedGoogle Scholar
• CDC. 2020. National Diabetes Statistics Report 2020. Estimates of Diabetes and Its Burden in the United States.
   Google Scholar
• Chachay, V. S., G. A. Macdonald, J. H. Martin, J. P. Whitehead, T. M. O’Moore-Sullivan, P. Lee, M. Franklin, K. Klein, P. J. Taylor, M. Ferguson, et al. 2014. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 12 (12):2092–103. doi: 10.1016/j.cgh.2014.02.024.
   PubMed Web of Science ®Google Scholar
• Chen, S., X. Zhao, L. Ran, J. Wan, X. Wang, Y. Qin, F. Shu, Y. Gao, L. Yuan, Q. Zhang, et al. 2015. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Digestive and Liver Disease 47 (3):226–32. doi: 10.1016/j.dld.2014.11.015.
   Google Scholar
• de Ligt, M., M. Bergman, R. M. Fuentes, H. Essers, E. Moonen-Kornips, B. Havekes, V. B. Schrauwen-Hinderling, and P. Schrauwen. 2020. No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: A randomized trial. The American Journal of Clinical Nutrition 112 (4):1029–38. doi: 10.1093/ajcn/nqaa125.
   PubMedGoogle Scholar
• Faghihzadeh, F., P. Adibi, R. Rafiei, and A. Hekmatdoost. 2014. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutrition Research 34 (10):837–43. doi: 10.1016/j.nutres.2014.09.005.
   PubMed Web of Science ®Google Scholar
• Goh, K. P., H. Y. Lee, D. P. Lau, W. Supaat, Y. H. Chan, and A. F. Y. Koh. 2014. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International Journal of Sport Nutrition and Exercise Metabolism 24 (1):2–13. doi: 10.1123/ijsnem.2013-0045.
   PubMed Web of Science ®Google Scholar
• Gregg, E. W., X. Zhuo, Y. J. Cheng, A. L. Albright, K. M. Venkat Narayan, and T. J. Thompson. 2014. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: A modelling study. The Lancet Diabetes & Endocrinology 2 (11):867–74. doi: 10.1016/S2213-8587(14)70161-5.
   PubMed Web of Science ®Google Scholar
• Higgins, J. P. T., D. G. Altman, P. C. Gøtzsche, P. Jüni, D. Moher, A. D. Oxman, J. Savović, K. F. Schulz, L. Weeks, and J. A. C. Sterne. 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (7829):343. doi: 10.1136/bmj.d5928.
   Google Scholar
• Higgins, J. P. T., and S. Green. 2011. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [Updated]. Cochrane Database of Systematic Reviews.
   Google Scholar
• Higgins, J. P. T., S. G. Thompson, J. J. Deeks, and D. G. Altman. 2003. Measuring inconsistency in meta-analyses. BMJ 327 (7414):557–60. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Hoseini, A., G. Namazi, A. Farrokhian, Ž. Reiner, E. Aghadavod, F. Bahmani, and Z. Asemi. 2019. The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food and Function 10:6042–6051. doi: 10.1039/c9fo01075k.
   PubMed Web of Science ®Google Scholar
• Kantartzis, K., L. Fritsche, M. Bombrich, J. Machann, F. Schick, H. Staiger, I. Kunz, R. Schoop, A. Lehn‐Stefan, M. Heni, et al. 2018. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes, Obesity & Metabolism 20 (7):1793–7. doi: 10.1111/dom.13268.
   PubMed Web of Science ®Google Scholar
• Khodabandehloo, H., S. S. Seyyedebrahimi, E. N. Esfahani, F. Razi, and R. Meshkani. 2018. Resveratrol supplementation decreases blood glucose without changing the circulating CD14 + CD16 + monocytes and inflammatory cytokines in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Nutrition Research 54:40–51. doi: 10.1016/j.nutres.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Kjaer, T. N., M. J. Ornstrup, M. M. Poulsen, H. Stødkilde-Jørgensen, N. Jessen, J. O. L. Jørgensen, B. Richelsen, and S. B. Pedersen. 2017. No beneficial effects of resveratrol on the metabolic syndrome: A randomized placebo-controlled clinical trial. The Journal of Clinical Endocrinology & Metabolism 102 (5):1642–51. doi: 10.1210/jc.2016-2160.
   PubMed Web of Science ®Google Scholar
• Köbe, T., A. V. Witte, A. Schnelle, V. A. Tesky, J. Pantel, J.-P. Schuchardt, A. Hahn, J. Bohlken, U. Grittner, and A. Flöel. 2017. Impact of resveratrol on glucose control, hippocampal structure and connectivity, and memory performance in patients with mild cognitive impairment. Frontiers in Neuroscience 11. doi: 10.3389/fnins.2017.00105.
   PubMedGoogle Scholar
• Liu, K., R. Zhou, B. Wang, and M. T. Mi. 2014. Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition 99 (6):1510–151. doi: 10.3945/ajcn.113.082024.
   PubMed Web of Science ®Google Scholar
• Malta, D. C., B. B. Duncan, M. I. Schmidt, Í. E. Machado, A. G. d Silva, R. T. I. Bernal, and C. A. Pereira. 2019. Prevalence of diabetes mellitus as determined by glycated hemoglobin in the Brazilian adult population, National Health Survey. Revista Brasileira de Epidemiologia 22 (Suppl 02). doi: 10.1590/1980-549720190006.supl.2.
   Google Scholar
• Marín-Peñalver, J. J., I. Martín-Timón, C. Sevillano-Collantes, and F. J. del Cañizo-Gómez. 2016. Update on the treatment of type 2 diabetes mellitus. World Journal of Diabetes 7 (17):354–95. doi: 10.4239/wjd.v7.i17.354.
   PubMed Web of Science ®Google Scholar
• Méndez-del Villar, M., M. González-Ortiz, E. Martínez-Abundis, K. G. Pérez-Rubio, and R. Lizárraga-Valdez. 2014. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metabolic Syndrome and Related Disorders 12 (10):497–501. doi: 10.1089/met.2014.0082.
   PubMed Web of Science ®Google Scholar
• Moher, D., A. Liberati, J. Tetzlaff, D. G. Altman, D. Altman, G. Antes, D. Atkins, and The PRISMA Group, et al. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine 6 (7):e1000097. doi: 10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Movahed, A., I. Nabipour, X. Lieben Louis, S. J. Thandapilly, L. Yu, M. Kalantarhormozi, S. J. Rekabpour, and T. Netticadan. 2013. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine 2013:11. doi: 10.1155/2013/851267.
   Google Scholar
• Muschik, D., J. Tetzlaff, K. Lange, J. Epping, S. Eberhard, and S. Geyer. 2017. Change in life expectancy with type 2 diabetes: A study using claims data from Lower Saxony, Germany. Population Health Metrics 15 (1):5. doi: 10.1186/s12963-017-0124-6.
   PubMedGoogle Scholar
• Nonomura, S., H. Kanagawa, and A. Makimoto. 1963. Chemical Constituents of Polygonaceous Plants. I. YAKUGAKU ZASSHI 83 (10):988–90. doi:10.1248/yakushi1947.83.10_988.
   PubMedGoogle Scholar
• Paez, A. 2017. Gray literature: An important resource in systematic reviews. Journal of Evidence-Based Medicine 10 (3):233–40. doi: 10.1111/jebm.12266.
   PubMedGoogle Scholar
• Patel, K. R., E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown. 2011. Clinical trials of resveratrol. Annals of the New York Academy of Sciences 1215 (1):161–9. doi: 10.1111/j.1749-6632.2010.05853.x.
   PubMedGoogle Scholar
• Pollack, R. M., N. Barzilai, V. Anghel, A. S. Kulkarni, A. Golden, P. O’Broin, D. A. Sinclair, et al. 2017. Resveratrol improves vascular function and mitochondrial number but not glucose metabolism in older adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences 72 (12):1703–1709. doi: 10.1093/gerona/glx041.
   PubMed Web of Science ®Google Scholar
• Poulsen, M. M., P. F. Vestergaard, B. F. Clasen, Y. Radko, L. P. Christensen, H. Stødkilde-Jørgensen, N. Møller, N. Jessen, S. B. Pedersen, and J. O. L. Jørgensen. 2013. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition . Diabetes 62 (4):1186–95. doi: 10.2337/db12-0975.
   PubMed Web of Science ®Google Scholar
• Saeedi, P., I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin, S. Colagiuri, L. Guariguata, A. A. Motala, K. Ogurtsova, et al. 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice 157:107843. doi: 10.1016/j.diabres.2019.
   PubMed Web of Science ®Google Scholar
• Sattarinezhad, A., J. Roozbeh, B. Shirazi Yeganeh, G. R. Omrani, and M. Shams. 2019. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial. Diabetes and Metabolism 45 (1):53–59. doi: 10.1016/j.diabet.2018.05.010.
   PubMedGoogle Scholar
• Seyyedebrahimi, S. S., H. Khodabandehloo, E. Nasli Esfahani, and R. Meshkani. 2018. The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial. Acta Diabetologica 55 (4):341–53. doi: 10.1007/s00592-017-1098-3.
   PubMed Web of Science ®Google Scholar
• Shaito, A., A. M. Posadino, N. Younes, H. Hasan, S. Halabi, D. Alhababi, A. Al-Mohannadi, W. M. Abdel-Rahman, A. H. Eid, G. K. Nasrallah, et al. 2020. Potential adverse effects of resveratrol: A literature review. International Journal of Molecular Sciences 21 (6):2084. doi: 10.3390/ijms06.
   PubMed Web of Science ®Google Scholar
• Szkudelski, T., and K. Szkudelska. 2011. Anti-diabetic effects of resveratrol. Annals of the New York Academy of Sciences 1215 (1):34–9. doi: 10.1111/j.1749-6632.2010.05844.x.
   PubMedGoogle Scholar
• Thaung Zaw, J. J., P. R. Howe, and R. H. Wong. 2020. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clinical Nutrition. doi: 10.1016/j.clnu.2020.08.025.
   PubMedGoogle Scholar
• Thazhath, S. S., T. Wu, M. J. Bound, H. L. Checklin, S. Standfield, K. L. Jones, M. Horowitz, and C. K. Rayner. 2016. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial. The American Journal of Clinical Nutrition 103 (1):66–70. doi: 10.3945/ajcn.115.117440.
   PubMed Web of Science ®Google Scholar
• Timmers, S., E. Konings, L. Bilet, R. H. Houtkooper, T. van de Weijer, G. H. Goossens, J. Hoeks, S. van der Krieken, D. Ryu, S. Kersten, et al. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism 14 (5):612–22. doi:10.1016/j.cmet.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Vallianou, N. G., A. Evangelopoulos, and C. Kazazis. 2013. Resveratrol and diabetes. The Review of Diabetic Studies 10.236. doi: 10.1900/RDS.2013.10.236.
   PubMedGoogle Scholar
• Van Der Made, S. M., J. Plat, and R. P. Mensink. 2015. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: A randomized, placebo-controlled crossover trial. PLoS One 10 (3):e0118393. doi: 10.1371/journal.pone.0118393.
   PubMed Web of Science ®Google Scholar
• Witte, A. V., L. Kerti, D. S. Margulies, and A. Floel. 2014. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. Journal of Neuroscience 34 (23):7862–70. doi: 10.1523/JNEUROSCI.0385-14.2014.
   PubMed Web of Science ®Google Scholar
• Wright, A. K., E. Kontopantelis, R. Emsley, I. Buchan, N. Sattar, M. K. Rutter, and D. M. Ashcroft. 2017. Life expectancy and cause-specific mortality in type 2 diabetes: A population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 40 (3):338–45. doi: 10.2337/dc16-1616.
   PubMed Web of Science ®Google Scholar
• Yoshino, J., C. Conte, L. Fontana, B. Mittendorfer, S.-i. Imai, K. B. Schechtman, C. Gu, I. Kunz, F. R. Fanelli, B. W. Patterson, et al. 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism 16 (5):658–64. doi: 10.10/j.cmet.2012.09.015.
   PubMed Web of Science ®Google Scholar
• Zare Javid, A., R. Hormoznejad, H. a Yousefimanesh, M. Zakerkish, M. H. Haghighi-Zadeh, P. Dehghan, and M. Ravanbakhsh. 2017. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytotherapy Research 31 (1):108–14. doi: 10.1002/ptr.5737.
   PubMedGoogle Scholar
• Zhu, X., C. Wu, S. Qiu, X. Yuan, and L. Li. 2017. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: Systematic review and meta-analysis. Nutrition and Metabolism. doi: 10.1186/s12986-017-0217-z.
   Google Scholar